Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Remedies Limited, a pharmaceutical intermediates and specialty chemicals manufacturer, posted weak Q3FY26 results with revenue falling 22% YoY to ₹21.11 crore. EBITDA dropped 32% to ₹6.73 crore and profit after tax declined 43% to ₹3.10 crore, as management blamed Christmas-related shipment delays (10–12% of topline deferred to Q4FY26), weak European demand, and price-led competition. For 9MFY26, revenue declined 10% YoY to ₹76.09 crore while PAT fell 30% to ₹11.50 crore, with EBITDA margin contracting 378 bps to 31.1%. Management framed FY26 as a 'year of consolidation' but highlighted operational positives including a newly commissioned pilot facility, on-track Block 7 expansion (commercial production expected H1FY27), and advancing CRAMS engagement with a Japanese client. Gradual improvement in business momentum is expected in FY27, supported by new product development and CRAMS traction.
The steep YoY declines across revenue, EBITDA, and PAT are likely to pressure the stock in the near term. However, management's commentary on capacity expansion, pilot facility ramp-up, and a healthy order pipeline through CRAMS may offer some comfort for investors with a longer-term horizon.